Results 61 to 70 of about 10,848 (199)

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Research advances of obinutuzumab in the treatment of membranous nephropathy

Linchuang shenzangbing zazhi
Membranous nephropathy （MN） is a common cause of adult nephrotic syndrome. Rituximab, a type Ⅰ anti-CD20 monoclonal antibody, is an effective treatment of MN.
Xiao-jing Lin, Jing Sun, Hao-yi Xiangli, Xuan-yi Du   +3 more
doaj   +1 more source

Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients

Transplantation Direct, 2023
Background. The THEORY study evaluated the effects of single and multiple doses of obinutuzumab, a type 2 anti-CD20 antibody that induces antibody-dependent cell-mediated cytotoxicity and direct cell death, in combination with standard of care in ...
Cary M. Looney, MS, Aaron Schroeder, BS, Erica Tavares, BSN, Jay Garg, MD, MBA, Thomas Schindler, PhD, Flavio Vincenti, MD, Robert R. Redfield, MD, Stanley C. Jordan, MD, Stephan Busque, MD, E. Steve Woodle, MD, Jared Khan, MS, Jeffrey Eastham, MS, Sandrine Micallef, PhD, Cary D. Austin, MD, PhD, Alyssa Morimoto, PhD   +14 more
doaj   +1 more source

BTK Inhibitor Ibrutinib Reduces Bispecific Antibody‐Related CRS Without Undermining the Anti‐Tumor Efficacy

Cancer Science, EarlyView.
BTK inhibition reprograms macrophages to suppress IL‐6/IL‐8/IL‐10‐driven CRS without compromising BsAb efficacy. ABSTRACT Bispecific antibodies (BsAbs) have shown marked efficacy in relapsed or refractory (R/R) B‐cell non‐Hodgkin lymphoma (B‐NHL). However, their clinical utility is constrained by cytokine release syndrome (CRS).
Jiaowu Cao, Dingyao Hu, Jie Lv, Jin Chai, Yue Wang, Jie Chen, Xiaoqiang Yan, Jun Zhu, Hui Yu   +8 more
wiley   +1 more source

Supplementary Figure S7 from Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells

, 2021
Confirmation of the combination effects in cells refractory to obinutuzumab-induced direct cell death.
Yoriko Yamashita-Kashima (15088800), Natsumi Kawasaki (15088803), Yasushi Yoshimura (6553670), Shigeki Yoshiura (15088806), Naoki Harada (1822495), Takaaki Fujimura (15088797)   +5 more
core   +1 more source

Bullous Eruption Associated With Loncastuximab Tesirine in a Patient With Diffuse Large B‐Cell Lymphoma

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Loncastuximab tesirine (LT) is an antibody‐drug conjugate (ADC), a novel class of therapeutics that combines a target‐specific monoclonal antibody with a cytotoxic agent via a chemical linker. LT has been approved in the United States as therapy for relapsed or refractory diffuse large B‐cell lymphoma (DLBCL).
Daniella Jaguan, Cuong Nguyen, Jennifer N. Choi   +2 more
wiley   +1 more source

Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain [PDF]

, 2016
To evaluate the cost-effectiveness of obinutuzumab in combination with chlorambucil (GClb) versus rituximab plus chlorambucil (RClb) in the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL) and with comorbidities that make ...
Krivasi, Tania, Orofino, Javier, Casado, Luis Felipe, Burgos, Amparo, González-Haba, Eva, Rubio-Rodríguez, Darío, Loscertales, Javier, Rubio-Terres, Carlos, Casado LF, Burgos A, Rubio-Rodríguez D, Loscertales J, González-Haba E, Orofino J, Rubio-Terres C, Krivasi T   +15 more
core   +1 more source

Supplementary Figure S3 from Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells

, 2021
The effects of obinutuzumab or chemotherapeutic agents in parental SU-DHL-4 cells.
Yoriko Yamashita-Kashima (15088800), Natsumi Kawasaki (15088803), Yasushi Yoshimura (6553670), Shigeki Yoshiura (15088806), Naoki Harada (1822495), Takaaki Fujimura (15088797)   +5 more
core   +1 more source

Gyriform Susceptibility Rim in Early Progressive Multifocal Leukoencephalopathy

Annals of Neurology, EarlyView.
Thor Linnet, Karan Dixit, Shailee Shah
wiley   +1 more source

Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...
Rhea Ahuja, Dedee Murrell
wiley   +1 more source